316 related articles for article (PubMed ID: 30087049)
1. How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country.
Castañeda-Orjuela C; De la Hoz-Restrepo F
Vaccine; 2018 Sep; 36(38):5766-5773. PubMed ID: 30087049
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
3. Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.
Haasis MA; Ceria JA; Kulpeng W; Teerawattananon Y; Alejandria M
PLoS One; 2015; 10(7):e0131156. PubMed ID: 26131961
[TBL] [Abstract][Full Text] [Related]
4. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
[TBL] [Abstract][Full Text] [Related]
5. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option.
Dorji K; Phuntsho S; Pempa ; Kumluang S; Khuntha S; Kulpeng W; Rajbhandari S; Teerawattananon Y
Vaccine; 2018 Mar; 36(13):1757-1765. PubMed ID: 29478752
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.
Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK
Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children.
Mezones-Holguín E; Bolaños-Díaz R; Fiestas V; Sanabria C; Gutiérrez-Aguado A; Fiestas F; Suárez VJ; Rodriguez-Morales AJ; Hernández AV
J Infect Dev Ctries; 2014 Dec; 8(12):1552-62. PubMed ID: 25500653
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia.
Lara C; De Graeve D; Franco F
Value Health Reg Issues; 2018 Dec; 17():21-31. PubMed ID: 29626706
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
Earnshaw SR; McDade CL; Zanotti G; Farkouh RA; Strutton D
BMC Infect Dis; 2012 Apr; 12():101. PubMed ID: 22530841
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia.
Ordóñez JE; Orozco JJ
Cost Eff Resour Alloc; 2015; 13():6. PubMed ID: 25878563
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
12. Pneumonia Prevention during a Humanitarian Emergency: Cost-effectiveness of Haemophilus Influenzae Type B Conjugate Vaccine and Pneumococcal Conjugate Vaccine in Somalia.
Gargano LM; Hajjeh R; Cookson ST
Prehosp Disaster Med; 2015 Aug; 30(4):402-11. PubMed ID: 26061190
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru.
Mezones-Holguin E; Canelo-Aybar C; Clark AD; Janusz CB; Jaúregui B; Escobedo-Palza S; Hernandez AV; Vega-Porras D; González M; Fiestas F; Toledo W; Michel F; Suárez VJ
Vaccine; 2015 May; 33 Suppl 1():A154-66. PubMed ID: 25919156
[TBL] [Abstract][Full Text] [Related]
14. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico.
Wasserman M; Palacios MG; Grajales AG; Baez/Revueltas FB; Wilson M; McDade C; Farkouh R
Hum Vaccin Immunother; 2019; 15(3):560-569. PubMed ID: 30156978
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.
Choi MJ; Kang SO; Oh JJ; Park SB; Kim MJ; Cheong HJ
Hum Vaccin Immunother; 2018; 14(8):1914-1922. PubMed ID: 29953307
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay.
Kieninger MP; Caballero EG; Sosa AA; Amarilla CT; Jáuregui B; Janusz CB; Clark AD; Castellanos RM
Vaccine; 2015 May; 33 Suppl 1():A143-53. PubMed ID: 25919155
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.
Boccalini S; Bechini A; Levi M; Tiscione E; Gasparini R; Bonanni P
Hum Vaccin Immunother; 2013 Mar; 9(3):699-706. PubMed ID: 23295824
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.
Robberstad B; Frostad CR; Akselsen PE; Kværner KJ; Berstad AK
Vaccine; 2011 Nov; 29(47):8564-74. PubMed ID: 21945264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
